Oncology

Knocking down MAPK4 resulted in the cells’ increased sensitivity to PI3K inhibitors and reduced breast cancer growth.

This high efficacy and low toxicity allow the combination treatment to provide a significant quality-of-life benefit to patients.

Germ cell tumors that occur in places other than the testicles and ovaries are very rare.

The FDA granted priority review to the combination of relatlimab and nivolumab in September 2021 based on the results of this study.

About 48% of individuals experienced a complete or partial response when treated with pembrolizumab, and about two-thirds also had a response that lasted more than 3 years.

Incorporating mental distress screenings during cancer care have been historically difficult, despite the fact that these patients tend to be vulnerable to mental health challenges.

Results of an analysis from the University of Eastern Finland show that supplementation for 5 years had no effect on total mortality or the incidence of these diseases in older individuals.

The recommendations include full immunization, including third doses and/or any approved boosters.

Proof-of-contest is inexpensive and quantifies specific antigens from a drop of blood within minutes.

Patients with EGFR exon 20 insertion mutation NSCLC account for approximately 1%-2% of NSCLC cases.

The submission is supported by data from MajesTEC-1, a multicenter clinical trial evaluating the safety and efficacy of teclistamab in adults with RRMM.

In the first quarter of 2022, Genprex expects to initiate its Acclaim-2 clinical trial to evaluate the treatment for individuals with histologically confirmed unresectable stage III or IV non–small cell lung cancer.

The metabolic protein SIRT3 reduces the pools of amino acids that cells use to make proteins and otherwise fuel their growth.

Telisotuzumab vedotin (Teliso-V, AbbVie) is an investigational antibody-drug conjugate that targets c-Met, a receptor tyrosine kinase that is overexpressed in tumors.

The Breakthrough Therapy Designation was granted based on data from the dose escalation portion of 2 expansion cohorts of a 3-cohort phase 1 study.

Results from a study conducted by the Institute for Health Metrics and Evaluation show that new cases jumped 26.3% over the same period.

Small GISTs may cause no symptoms and may grow so slowly that they have no serious effects.

Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most often for patients.

The study authors sought to determine the proportion of states that elected to follow CDC recommendations by identifying each state’s COVID-19 vaccination webpage through keyword-based internet search and set out to identify information about vaccinations for patients with cancer.

Melanoma is responsible for 80% of skin cancer deaths.

The increasing economic burden of treatment may impact patient outcomes.

Burnout in pharmacy can be managed with the proper planning and the right techniques for your preference.

The goal of the financial counselor is to identify available funding for patient care in a timely manner, but the sheer number of resources and variables involved results in a long, tedious process.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

Chemotherapy-induced nausea and vomiting can impact patients’ treatment outcomes.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the next steps for clinical research assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

More transparent drug pricing could improve patient care.

The FDA looks to address a lack of diversity in cancer drug trials.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.